CR6881A - PIRAZOL DERIVATIVES - Google Patents

PIRAZOL DERIVATIVES

Info

Publication number
CR6881A
CR6881A CR6881A CR6881A CR6881A CR 6881 A CR6881 A CR 6881A CR 6881 A CR6881 A CR 6881A CR 6881 A CR6881 A CR 6881A CR 6881 A CR6881 A CR 6881A
Authority
CR
Costa Rica
Prior art keywords
formula
compounds
pharmaceutical compositions
methods
treat
Prior art date
Application number
CR6881A
Other languages
Spanish (es)
Inventor
Blair Cooper Cristhopher
John Helal Cristopher
Allen Sanner Mark
T Wager Travis
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR6881A publication Critical patent/CR6881A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION PROPORCIONA COMPUESTOS DE LA FORMULA 1, DONDE R1, R2, R3 Y R4 SON COMO SE DEFINEN Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SE INDICAN QUE LOS COMPUESTOS DE LA FORMULA 1 TIENEN ACTIVIDAD PARA INHIBIR LAS CDK5, CDK2 Y GSK-3. PROPORCIONA COMPOSICIONES FARMACEUTICAS Y METODOS QUE COMPRENDEN COMPUESTOS DE LA FORMULA 1 PARA TRATAR Y PREVENIR ENFERMEDADES Y CONDICIONES QUE IMPLICAN CRECIMIENTO CELULAR ANORMAL, TALES COMO EL CANCER Y ENFERMEDADES Y CONDICIONES NEURODEGENERATIVAS Y LAS AFECTADAS POR LA NEUROTRANSMISION DE LA DOPAMINA. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y METODOS QUE COMPRENDEN COMPUESTOS DE LA FORMULA 1 PARA TRATAR LA FERTILIDAD MASCULINA Y LA MOTILIDAD ESPERMATICA, DIABETES MELITUS, DETERIORO A LA TOLERANCIA A LA GLUCOSA, SINDROME METABOLICO O SINDROME X, SINDROME DE POLIQUISTOSIS OVARICA, ADOPOGENESIS Y OBESIDAD, MIOGENESIS Y FRAGILIDAD.THE INVENTION PROVIDES COMPOUNDS OF FORMULA 1, WHERE R1, R2, R3 AND R4 ARE AS DEFINED AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS. IT IS INDICATED THAT THE COMPOUNDS OF FORMULA 1 HAVE ACTIVITY TO INHIBIT THE CDK5, CDK2 AND GSK-3. PROVIDES PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE COMPOUNDS OF FORMULA 1 TO TREAT AND PREVENT DISEASES AND CONDITIONS THAT IMPLY ABNORMAL CELLULAR GROWTH, SUCH AS CANCER AND NEURODEGENERATIVE DISEASES AND AFFECTURING OPENING. ALSO DESCRIBE PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE COMPOUNDS OF FORMULA 1 TO TREAT MALE FERTILITY AND SPERMATIC MOTILITY, MELITUS DIABETES, DETERIORATION TO GLUCOSE TOLERANCE, SYNDROME SYMPOSIS, SYMBOLOSIS, ADOPE SYNTHEOPHYOPHYOPHYOPHYOPHYOPHYOPHYMOPEOLOGY, METHODSOPHYOPHYOPHYMOPEOLOGY, METHODOLOGY, SYNTHEOPHYSIS, ADOPTOLOGY MIOGENESIS AND FRAGILITY.

CR6881A 2000-08-31 2003-01-15 PIRAZOL DERIVATIVES CR6881A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
CR6881A true CR6881A (en) 2004-03-11

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6881A CR6881A (en) 2000-08-31 2003-01-15 PIRAZOL DERIVATIVES

Country Status (38)

Country Link
EP (1) EP1313710A1 (en)
JP (1) JP2004507526A (en)
KR (1) KR20030027093A (en)
CN (1) CN1518543A (en)
AP (1) AP2001002266A0 (en)
AR (1) AR035345A1 (en)
AU (1) AU2001280009A1 (en)
BG (1) BG107455A (en)
BR (1) BR0113574A (en)
CA (1) CA2420363A1 (en)
CR (1) CR6881A (en)
CZ (1) CZ2003468A3 (en)
DO (1) DOP2001000243A (en)
DZ (1) DZ3398A1 (en)
EA (1) EA200300205A1 (en)
EC (1) ECSP034480A (en)
EE (1) EE200300085A (en)
GT (1) GT200100179A (en)
HN (1) HN2001000192A (en)
HR (1) HRP20030140A2 (en)
HU (1) HUP0302669A3 (en)
IL (1) IL154016A0 (en)
IS (1) IS6687A (en)
MA (1) MA26946A1 (en)
MX (1) MXPA03001785A (en)
NO (1) NO20030958D0 (en)
NZ (1) NZ523656A (en)
OA (1) OA12368A (en)
PA (1) PA8528101A1 (en)
PE (1) PE20020470A1 (en)
PL (1) PL360742A1 (en)
SK (1) SK2002003A3 (en)
SV (1) SV2002000618A (en)
TN (1) TNSN01132A1 (en)
UY (1) UY26909A1 (en)
WO (1) WO2002018346A1 (en)
YU (1) YU14703A (en)
ZA (1) ZA200301064B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP4105948B2 (en) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100909665B1 (en) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
DE60222286T2 (en) * 2001-09-27 2008-06-19 Laboratoires Serono S.A., Coinsins PROCESS FOR INCREASING THE TESTOSTERONE MIRROR
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
CA2492673A1 (en) * 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
BR0315158A (en) 2002-10-09 2005-08-16 Pfizer Prod Inc Pyrazole Compounds for the Treatment of Neurodegenative Disorders
JP2006504755A (en) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Pyridazine compounds as GSK-3 inhibitors
ATE410415T1 (en) * 2003-02-27 2008-10-15 Smithkline Beecham Corp NEW CONNECTIONS
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diaryl ureas for diseases mediated by pdgfr
EP1633350B1 (en) * 2003-06-05 2012-10-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
KR101204247B1 (en) * 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases cdk and glycogen synthase kinase-3 gsk-3 modulators
ES2297490T3 (en) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation OMEGA-CARBOXIARILDIFENILUREA FLUORO REPLACED FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS.
BRPI0412820A (en) * 2003-07-25 2006-09-26 Pfizer aminopyrazole compounds and use as chk1 inhibitors
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EP1742921A2 (en) * 2004-04-21 2007-01-17 AstraZeneca AB Pyrazole derivatives useful for the treatment of cancer
ATE517885T1 (en) 2004-04-30 2011-08-15 Bayer Healthcare Llc SUBSTITUTED PYRAZOLYL UREA DERIVATIVES FOR THE TREATMENT OF CANCER
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006004865A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
ES2375735T3 (en) 2005-02-04 2012-03-05 Astrazeneca Ab USEFUL PIRAZOLILAMINOPIRIDINE DERIVATIVES AS QUINASE INHIBITORS.
JPWO2006085685A1 (en) * 2005-02-09 2008-06-26 武田薬品工業株式会社 Pyrazole compounds
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
BRPI0610184A2 (en) 2005-05-16 2012-09-25 Astrazeneca Ab compound, pharmaceutically acceptable salt of a compound, process for preparing a compound or a pharmaceutically acceptable salt thereof, use of a compound or a pharmaceutically acceptable salt thereof, methods for inhibiting trk activity, for cancer treatment or prophylaxis and for producing an antiproliferative effect on a warm-blooded animal, and, pharmaceutical composition
EP1741708A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
ES2535854T3 (en) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Substituted Pyrazole Compounds
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2533241T3 (en) 2005-11-03 2015-04-08 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007311444B2 (en) 2006-10-18 2012-11-29 Periness Ltd. Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
AU2007312165A1 (en) 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
CN101868459B (en) 2007-09-21 2013-12-18 阿雷生物药品公司 Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for treatment of diabetes mellitus
WO2009130900A1 (en) * 2008-04-24 2009-10-29 日本曹達株式会社 Oxime derivative, intermediate compound, and plant disease control agent
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105237530A (en) 2009-04-03 2016-01-13 豪夫迈罗氏公司 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US20110081316A1 (en) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
PT2672967T (en) 2011-02-07 2018-12-07 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
AU2014308182B2 (en) 2013-08-16 2018-03-08 Merck Patent Gmbh 3-substituted cyclopentylamine derivatives
CN106580986B (en) * 2016-11-28 2017-09-15 王保亮 A kind of pharmaceutical composition for treating teen bra
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
AU2020213761C1 (en) * 2019-01-31 2023-08-10 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
WO2022135442A1 (en) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2 inhibitor and preparation method therefor
TW202309030A (en) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2 degraders and uses thereof
CR20230598A (en) 2021-06-28 2024-04-25 Blueprint Medicines Corp Cdk2 inhibitors
WO2023274397A1 (en) * 2021-07-01 2023-01-05 上海拓界生物医药科技有限公司 Cdk2 inhibitor, preparation method therefor and use thereof
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
TW202325280A (en) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 An aminopyrazole derivative, preparation method and use thereof
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299156B6 (en) * 1997-12-22 2008-05-07 Bayer Corporation Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use
KR100579792B1 (en) * 1998-05-13 2006-05-12 동화약품공업주식회사 Novel 2,5-pyridinedicarboxylic acid derivatives
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
US6958333B1 (en) * 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
ES2249270T3 (en) * 1999-08-12 2006-04-01 Pharmacia Italia S.P.A. DERIVATIVES OF 3 (5) -AMINOPIRAZOL, PROCEDURE FOR ITS PREPARATION AND ITS USE AS ANTITUMOR AGENTS.
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EA200200411A1 (en) * 1999-11-30 2002-10-31 Пфайзер Продактс Инк. 2,4-DIAMINOPYRIMIDINE COMPOUNDS USEFUL AS IMMUNOSUPRESSORS
JP2004501083A (en) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド Pyrazole for inhibiting protein kinases

Also Published As

Publication number Publication date
HRP20030140A2 (en) 2003-04-30
MXPA03001785A (en) 2003-06-04
GT200100179A (en) 2002-04-22
HN2001000192A (en) 2001-08-28
IS6687A (en) 2003-01-16
HUP0302669A2 (en) 2003-12-29
EA200300205A1 (en) 2003-06-26
HUP0302669A3 (en) 2004-03-29
OA12368A (en) 2004-04-13
ZA200301064B (en) 2004-04-19
PA8528101A1 (en) 2002-07-30
MA26946A1 (en) 2004-12-20
IL154016A0 (en) 2003-07-31
DOP2001000243A (en) 2002-10-15
CA2420363A1 (en) 2002-03-07
CN1518543A (en) 2004-08-04
JP2004507526A (en) 2004-03-11
BG107455A (en) 2003-09-30
TNSN01132A1 (en) 2005-11-10
CZ2003468A3 (en) 2004-05-12
AR035345A1 (en) 2004-05-12
AU2001280009A1 (en) 2002-03-13
EP1313710A1 (en) 2003-05-28
SK2002003A3 (en) 2004-04-06
BR0113574A (en) 2003-07-22
NZ523656A (en) 2004-11-26
PE20020470A1 (en) 2002-06-18
NO20030958L (en) 2003-02-28
DZ3398A1 (en) 2002-03-07
KR20030027093A (en) 2003-04-03
UY26909A1 (en) 2002-03-22
NO20030958D0 (en) 2003-02-28
SV2002000618A (en) 2002-10-24
EE200300085A (en) 2004-12-15
YU14703A (en) 2006-05-25
AP2001002266A0 (en) 2001-09-30
ECSP034480A (en) 2003-03-31
WO2002018346A1 (en) 2002-03-07
PL360742A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
CR6881A (en) PIRAZOL DERIVATIVES
GT200100147A (en) IMIDAZOL DERIVATIVES
CR8147A (en) PIRIDO DERIVATIVES 2, 1A-ISOQUINOLINE, AS DPP-IV INHIBITORS
UY26782A1 (en) DERIVATIVES OF BENZOTIAZOLE
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
DOP2006000169A (en) BETA-SECRETASE SPIROPIPERIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PA8442001A1 (en) DERIVATIVES OF CONDENSED BICYCLIC PIRIMIDINE
PA8550101A1 (en) DERIVATIVES OF BENZAMIDA TIAZOL AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS, AND METHODS FOR USE
GT200500375A (en) PIPERIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
CY1105301T1 (en) ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS
ECSP10010506A (en) Derivatives of 1-heterocyclyl-1,5-dihydro-pyrazol [3,4-D] pyrimidino-4-one and its use as PDE9A inhibitors.
UY28135A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8507601A1 (en) NEW BENZOIMIDAZOL USEFUL DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
CO4810375A1 (en) DERIVATIVES OF 9-AMINO-3-KETO Erythromycin
AR020032A1 (en) DERIVATIVES OF 1,3-METHYL Erythromycin.
PA8583101A1 (en) NEW COMPOUNDS OF ISOTIAZOL AND ISOXAZOL AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
AR021843A1 (en) DERIVATIVES OF PROPANOLAMINE SUBSTITUTED WITH HETEROCICLES, PROCEDURE FOR THEIR PREPARATION, AND ITS USE.
CY1108584T1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICINES FOR TREATMENT OF STRUCTURE
GT200100209A (en) BRIDGE DERIVATIVES OF PIPERAZINA.
AR025046A1 (en) IL-5 NON-STEROID INHIBITORS, PROCEDURES AND INTERMEDIARIES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITORS
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UY27034A1 (en) PIRIMIDINE DERIVATIVES
CY1106711T1 (en) SUBSTITUTED PROPANE-1,3-DIAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
PA8450901A1 (en) Erythromycin derivatives
AR049343A1 (en) THIOETER DERIVATIVES, THEIR OBTAINING AND USE OF THE SAME AS PHARMACEUTICAL AGENTS

Legal Events

Date Code Title Description
FD Application declared void or lapsed